<DOC>
	<DOCNO>NCT02025868</DOCNO>
	<brief_summary>Thilao multi-country , phase 2b , non-randomized study , Burkina Faso , Cote d'Ivoire , Mali Senegal , West Africa . HIV-1 adults 2nd-line ART virologic failure ( plasma HIV-1 RNA &gt; 1000 copies/ml ) recruit follow two phase : - First , 12-week intentive adherence reinforcement phase , patient continue 2nd-line ART , see repeatidly counsel educational training adherence , offer possibility phone , SMS home visit contact social worker ; - Second , 48-week phase , : - Patients successfully resuppressed end first phase continue 2nd-line ART adherence reinforcement ; - Patients persitent virologic failure switch darunavir/r + raltegravir-based 3rd-line ART . Genotype resistance test perform retrospectively frozen sample . The main outcome percentage patient plasma HIV-1 viral RNA &lt; 50 copies/ml 64 week .</brief_summary>
	<brief_title>Third Line Antiretroviral Treatment Optimization Sub-Saharan Africa</brief_title>
	<detailed_description>Main objective To estimate , sub-Saharan African HIV-1 infect adult fail NNRTI-base first-line ART PI-based second-line ART : 1 . The efficacy ( associated factor ) 12 week intensive 3-months adherence reinfrocement phase ; 2 . In patient successfully resuppress 12 week : The percentage patient still continue succesfull virologic supression 2nd-line ART 64 week ( factor associate success ) ; 3 . In patient persistent failure 12 week : The efficacy ( associated factor ) 64 week darunavir/r + raltegravir-based 3rd-line regimen . Number participant : 200 Main outcome : - At 12 week : Proportion patient plasma HIV-1 RNA &lt; 400 copies/ml and/or decrease plasma HIV-1 RNA &gt; 2 log10 copies/ml inclusion 12 week ; - At 64 week : proportion patient plasma HIV-1 RNA &lt; 50 copies/ml . Inclusion criterion : - Age &gt; 18 year - Documented HIV-1 infection . - History fail NNRTI-based 1st-line ART - Current PI-based 2nd-line ART &gt; 6 month - Plasma HIV-1 RNA &gt; 1000 copies/ml - Signed informed consent</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Age &gt; 18 year Documented HIV1 infection History failing NNRTIbased 1stline ART Current PIbased 2ndline ART &gt; 6 month Plasma HIV1 RNA &gt; 1000 copies/ml Signed informed consent HIV2 infection Any Severe clinical event exploration History treatment include darunavir raltegravir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Africa</keyword>
	<keyword>Antiretroviral Treatment</keyword>
	<keyword>Adherence reinforcement</keyword>
	<keyword>Third line ART</keyword>
	<keyword>Second line ART</keyword>
	<keyword>Virologic failure</keyword>
	<keyword>Adults</keyword>
</DOC>